Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics
AuthorBuzzi, Raphael M
Owczarek, Catherine M
Hardy, Matthew P
Buehler, Paul W
Schaer, Dominik J
PublisherAmerican Chemical Society
MetadataShow full item record
AbstractCell-free hemoglobin (Hb) is a driver of disease progression in conditions with intravascular or localized hemolysis. Genetic and acquired anemias or emergency medical conditions such as aneurysmal subarachnoid hemorrhage involve tissue Hb exposure. Haptoglobin (Hp) captures Hb in an irreversible protein complex and prevents its pathophysiological contributions to vascular nitric oxide depletion and tissue oxidation. Preclinical proof-of-concept studies suggest that human plasma-derived Hp is a promising therapeutic candidate for several Hb-driven diseases. Optimizing the efficacy and safety of Hb-targeting biotherapeutics may require structural and functional modifications for specific indications. Improved Hp variants could be designed to achieve the desired tissue distribution, metabolism, and elimination to target hemolytic disease states effectively. However, it is critical to ensure that these modifications maintain the function of Hp. Using transient mammalian gene expression of Hp combined with co-transfection of the pro-haptoglobin processing protease C1r-LP, we established a platform for generating recombinant Hp-variants. We designed an Hpβ-scaffold, which was expressed in this system at high levels as a monomeric unit (mini-Hp) while maintaining the key protective functions of Hp. We then used this Hpβ-scaffold as the basis to develop an initial proof-of-concept Hp fusion protein using human serum albumin as the fusion partner. Next, a hemopexin-Hp fusion protein with bispecific heme and Hb detoxification capacity was generated. Further, we developed a Hb scavenger devoid of CD163 scavenger receptor binding. The functions of these proteins were then characterized for Hb and heme-binding, binding of the Hp-Hb complexes with the clearance receptor CD163, antioxidant properties, and vascular nitric oxide sparing capacity. Our platform is designed to support the generation of innovative Hb scavenger biotherapeutics with novel modes of action and potentially improved formulation characteristics, function, and pharmacokinetics. © 2021 The Authors. Published by American Chemical Society.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16418
- CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin.
- Authors: Schaer DJ, Schaer CA, Buehler PW, Boykins RA, Schoedon G, Alayash AI, Schaffner A
- Issue date: 2006 Jan 1
- Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification.
- Authors: Buehler PW, Abraham B, Vallelian F, Linnemayr C, Pereira CP, Cipollo JF, Jia Y, Mikolajczyk M, Boretti FS, Schoedon G, Alayash AI, Schaer DJ
- Issue date: 2009 Mar 12
- Phenotype-specific recombinant haptoglobin polymers co-expressed with C1r-like protein as optimized hemoglobin-binding therapeutics.
- Authors: Schaer CA, Owczarek C, Deuel JW, Schauer S, Baek JH, Yalamanoglu A, Hardy MP, Scotney PD, Schmidt PM, Pelzing M, Soupourmas P, Buehler PW, Schaer DJ
- Issue date: 2018 Mar 15
- The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging.
- Authors: Thomsen JH, Etzerodt A, Svendsen P, Moestrup SK
- Issue date: 2013
- Haptoglobin Is a Divergent MASP Family Member That Neofunctionalized To Recycle Hemoglobin via CD163 in Mammals.
- Authors: Redmond AK, Ohta Y, Criscitiello MF, Macqueen DJ, Flajnik MF, Dooley H
- Issue date: 2018 Oct 15